Slynd® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….
Month: July 2023
Slynd® (drospirenone) is now covered by the Régie de l’assurance maladie du Québec
Slynd® Slynd® is now reimbursed for 100% of Quebec women to whom it is indicated….
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World’s Largest Niemann-Pick Type C1 Disease Cohort
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment…
CENTOGENE Biodatabank Reveals Unique Genetic Variants in World’s Largest Niemann-Pick Type C1 Disease Cohort
Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment…
RIFF Cannabis Brand Launches New THC Beverages for Summer
New RIFF Wild Raspberry Lemonade and RIFF Blue Raspberry Ice Sparkling Drinks Infused with 10mg…
RIFF Cannabis Brand Launches New THC Beverages for Summer
New RIFF Wild Raspberry Lemonade and RIFF Blue Raspberry Ice Sparkling Drinks Infused with 10mg…
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors
WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or…
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and…
Evelo Biosciences Closes $25.5 Million Private Placement
Restructures and reduces secured debt with Horizon Technology Finance Corporation Appoints two new members and…
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol Q2 2023…
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
Sudocetaxel zendusortide Phase 1 Trial to resume following FDA agreement to amended protocol Q2 2023…
Omega Therapeutics Appoints Chris Schade to its Board of Directors
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise CAMBRIDGE, Mass., July 12, 2023 (GLOBE…
Omega Therapeutics Appoints Chris Schade to its Board of Directors
Accomplished Industry Veteran Brings Deep Strategic and Operational Expertise CAMBRIDGE, Mass., July 12, 2023 (GLOBE…
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo…
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics
SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics SparingVision remains focused on in vivo…
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination…
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination candidate GMRx2
George Medicines completes recruitment of first Phase III hypertension trial investigating novel single-pill triple combination…
Tilray Brands, Inc. to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on July 26, 2023
NEW YORK and LEAMINGTON, Ontario, July 12, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…
Tilray Brands, Inc. to Announce Fourth Quarter and Fiscal Year 2023 Financial Results on July 26, 2023
NEW YORK and LEAMINGTON, Ontario, July 12, 2023 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray”…